Auricular Vagus Nerve Stimulation (aVNS) in Chronic Spinal Cord Injuries (SCI)
Not Applicable
Recruiting
- Conditions
- Spinal Cord Injuries
- Registration Number
- NCT06588608
- Lead Sponsor
- University of Miami
- Brief Summary
The purpose of this research is to test if Auricular Vagal Nerve Stimulation (aVNS) is safe in persons with spinal cord injury (SCI).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
- Males and females
- Chronic (equal or greater to 1 year) motor-complete and incomplete SCI Abbreviated Injury Scale (AIS) of A or B at the C5-T10 levels
Exclusion Criteria
- Pregnant or breastfeeding
- Prisoner
- Failure to satisfy inclusion criteria
- Previous bariatric surgery
- Active implantable devices (such as pacemakers)
- Skin irritation or damage at the site (ear)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Number of Treatment-related Adverse Events (AEs) Up to 2 weeks Safety will be reported as the number of treatment-related AEs assessed by study PI or physician
Number of subjects that complete the study Up to 2 weeks Safety will be determined by number of subjects that complete the two study, visits (in total, two weeks).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie aVNS effects on autonomic nervous system modulation in chronic SCI patients?
How does auricular vagus nerve stimulation compare to pharmacological treatments for cardiovascular dysfunction in SCI?
Which biomarkers correlate with improved glycemic homeostasis in NCT06588608 aVNS trial for SCI participants?
What adverse events are associated with transcutaneous auricular VNS in chronic SCI populations and mitigation strategies?
Are there synergistic effects when combining aVNS with metformin or beta-blockers for autonomic dysregulation in SCI?
Trial Locations
- Locations (1)
University of Miami
🇺🇸Miami, Florida, United States
University of Miami🇺🇸Miami, Florida, United StatesPatricia Graham, MS, CCRCContact3052435119pgraham1@med.miami.eduPatrick Ganzer, PhDContact